ENVALITH
勤次郎株式会社 logo

Kinjiro Co.,Ltd.

4013Growth MarketInformation & Communication

勤次郎株式会社 logo
Kinjiro Co.,Ltd.4013

Governance

Transitioned from a company with a board of corporate auditors to a company with an audit and supervisory committee in March 2025. The board of directors consists of 9 members (including 3 outside directors, all of whom serve on the audit and supervisory committee), and an executive officer system has been established alongside a framework for partial delegation of business execution authority. Representative Director Minoru Kamura qualifies as a controlling shareholder, and the company's articles of incorporation explicitly stipulate a policy for protecting minority shareholders. No establishment of a nomination committee or compensation committee is disclosed in the annual securities report.

Outside Director Ratio

33.3%

Nomination Committee

Not Established

Compensation Committee

Not Established

Risk Management

A system has been established to detect and prevent risks at an early stage through the Board of Directors, the Management Committee, the Executive Officers' Meeting, and the Compliance Committee. The Internal Audit Office (a head plus 2 staff) and the Audit and Supervisory Committee provide oversight functions, working in coordination with external experts such as retained attorneys, tax accountants, and labor and social security attorneys. An internal whistleblowing system and a Tripartite Audit Council (held 5 times per year) have been put in place, maintaining a multi-layered management framework based on the Risk Management Regulations.

Shareholder Returns

The basic policy is a single year-end dividend once per year, with actual FY2025 (ending December 2025) dividend at ¥10.00 per share. The FY2026 (ending December 2026) forecast is also ¥10.00 per share (¥0.00 at second quarter-end, ¥10.00 at year-end), maintaining the same amount as the previous period. No new share buyback is mentioned.

Dividend Policy

The basic policy is a single year-end dividend once per year, with the record date set as December 31 each year. The actual dividend for FY2025 (ending December 2025) was ¥10.00 per share (¥0.00 at second quarter-end, ¥10.00 at year-end). The forecast for FY2026 (ending December 2026) is also ¥10.00 per share (¥0.00 at second quarter-end, ¥10.00 at year-end), unchanged from the previous period. In March 2026, a dividend from surplus of ¥198,637 thousand was already paid (the year-end dividend for FY2025 (ending December 2025)).

Dividend

Paying

Share Buyback

None

Shareholder Benefits

None

ESG

Certified as an "Excellent Health Management Corporation" for 9 consecutive years. The company discloses achievements including a 100% regular health checkup participation rate, 100% stress check participation rate, 100% specific health guidance implementation rate, and 100% male childcare leave uptake rate, along with a 9% female manager ratio and average overtime hours of 16 hours. The company promotes health management utilizing its own product "Universal Kinjiro," and also conducts internal health initiatives and social contribution activities through the "Kinjiro Genki Project," led by younger employees. No quantitative disclosures related to climate change are included in the annual securities report.

Last updated: March 19, 2026